Stock Forecast

  Insulet Corporation ( PODD) Stock. Should you Buy or Sell?    $ 268.91

-0.72 (-0.27 %)

Insulet Corporation Analysis

Updated on 10-09-2022
Symbol PODD
Price $268.91
Beta 0.723
Volume Avg. $396.51 thousand
Market Cap $18.66 B
52 Week Range $181.0 - $324.81

Insulet Corporation opened the day at $268.91 which is -0.27 % on yesterday's close. Insulet Corporation has a 52 week high of $324.81 and 52 week low of $181.0, which is a difference of $143.81. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $18.66 B and total net profit is $1098800000 which means the company is trading at 16.99 times profit to market capitalization. Theoretically, if you were to buy Insulet Corporation for $18.66 B, it would take 15 years to get your money back. Insulet Corporation are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Insulet Corporation Stock Forecast - Is Insulet Corporation a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreStrong Buy
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value

PE Ratio 517.135
Dividend Yiel 0.000
Net Profit Margin 0.029

Valuing Insulet Corporation

Price Book Value Ratio 44.154 Price To Book Ratio 44.154
Price To Sales Ratio 15.831 Price Earnings Ratio 539.032

How liquid is Insulet Corporation

Current Ratio 4.687
Quick Ratio 3.272


Debt Ratio 0.800 Debt Equity Ratio 4.004
Long Term Debt To Capitalization 0.766 Total Debt To Capitalization 0.770

Latest news about Insulet Corporation

Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up

Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.

Date : 09/08/2022

Insulet Corporation (PODD) CEO Jim Hollingshead on Q2 2022 Results - Earnings Call Transcript

Insulet Corporation (NASDAQ:PODD ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and Chief Executive Officer Wayde McMillan - Executive Vice President and Chief Financial Officer Bret Christensen - Executive Vice President and Chief Commercial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JP Morgan Travis Steed - Bank of America Steve Lichtman - Oppenheimer Chris Pasquale - Nephron Research Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Margaret Kaczor - William Blair Jayson Bedford - Raymond James Brian Kennedy - Cowen Matthew O'Brien - Piper Sandler Jeff Johnson - Baird Operator Good afternoon, ladies and gentlemen and welcome to the Insulet Corporation Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Date : 07/08/2022

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at four upcoming investor conferences (all Eastern Time): The Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 4:30 p.m. The 2022 Wells Fargo Healthcare conference on Friday, September 9, 2022, at 8:00 a.m. The Morgan Stanley 20th Annual Global Healthca

Date : 05/08/2022

Insulet: Bullish Factors For Portfolio Inclusion

Insulet presents with compelling near-term upside capture over the coming 4-6 months. We estimate the stock to continue re-rating to the upside, based on a confluence of market, fundamental and technical factors.

Date : 23/07/2022

Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2022 on August 4, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor R

Date : 30/06/2022

About Insulet Corporation

CEO : Ms. Shacey Petrovic
Sector : Healthcare
Industry : Medical Devices

Website :

Exchange : NASDAQ Global Select

Description :

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

My Newsletter

Sign Up For Updates & Newsletters